Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (5060)
All Articles published online
|
Publishing Process of This Article
|
Jan 27, 2013 (publication date) through Apr 24, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Hepatology
ISSN
1948-5182
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Sezgin Göksu S, Bilal Ş, Coşkun HŞ. Hepatitis B reactivation related to everolimus. World J Hepatol 2013; 5(1): 43-45 [PMID: 23383366 DOI: 10.4254/wjh.v5.i1.43] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v5/i1/43.htm |
| Number | Citing Articles |
| 1 |
Elaheh Kordzadeh-Kermani, Hossein Khalili, Iman Karimzadeh, Mohammadreza Salehi. <p>Prevention Strategies to Minimize the Infection Risk Associated with Biologic and Targeted Immunomodulators</p>. Infection and Drug Resistance 2020; : 513 doi: 10.2147/IDR.S233137
|
| 2 |
S. Yazaki, T. Yamauchi, T. Higashi. High hepatitis B virus screening rate among patients receiving systemic anticancer treatment in Japan. International Journal of Clinical Oncology 2020; 25(7): 1327 doi: 10.1007/s10147-020-01655-4
|
| 3 |
Seungtaek Lim, Jungwoo Han, Gun Min Kim, Kwang‐Hyub Han, Hye Jin Choi. Hepatitis B viral load predicts survival in hepatocellular carcinoma patients treated with sorafenib. Journal of Gastroenterology and Hepatology 2015; 30(6): 1024 doi: 10.1111/jgh.12898
|
| 4 |
Shoko Sonobe, Toru Arai, Yasushi Tanimoto, Chikatoshi Sugimoto, Masanori Kitaichi, Masanori Akira, Takahiko Kasai, Masaki Hirose, Yoshikazu Inoue. Successful Sirolimus Treatment of Lymphangioleiomyomatosis in a Hepatitis B Virus Carrier. Internal Medicine 2019; 58(4): 569 doi: 10.2169/internalmedicine.1329-18
|
| 5 |
Shih-Chun Chang, Chun-Yi Tsai, Keng-Hao Liu, Shang-yu Wang, Jun-Te Hsu, Ta-Sen Yeh, Chun-Nan Yeh. Everolimus Related Fulminant Hepatitis in Pancreatic Neuroendocrine Tumor With Liver Metastases: A Case Report and Literature Review. Frontiers in Endocrinology 2021; 12 doi: 10.3389/fendo.2021.639967
|
| 6 |
Matthias S. Matter, Thomas Decaens, Jesper B. Andersen, Snorri S. Thorgeirsson. Targeting the mTOR pathway in hepatocellular carcinoma: Current state and future trends. Journal of Hepatology 2014; 60(4): 855 doi: 10.1016/j.jhep.2013.11.031
|
| 7 |
Satoshi Takahashi, Soichi Arakawa, Kiyohito Ishikawa, Jun Kamei, Kanao Kobayashi, Katsumi Shigemura, Satoru Takahashi, Yoshiki Hiyama, Ryoichi Hamasuna, Hiroshi Hayami, Satoshi Yazawa, Mitsuru Yasuda, Yoshikazu Togo, Shingo Yamamoto, Koichiro Wada, Toyohiko Watanabe. Guidelines for Infection Control in the Urological Field, including Urinary Tract Management (revised second edition). International Journal of Urology 2021; 28(12): 1198 doi: 10.1111/iju.14684
|
| 8 |
Annelieke E. C. A. B. Willemsen, Filip Y. De Vos, Anne Jansen, Maaike de Boer, Vivianne C. G. Tjan-Heijnen, Carla M. L. van Herpen. Diagnostic challenges of respiratory adverse events during everolimus treatment. Targeted Oncology 2014; 9(3): 287 doi: 10.1007/s11523-014-0310-4
|
| 9 |
Carmine D'Aniello, Marco Maruzzo, Umberto Basso. Prevention of Hepatitis B Virus Reactivation With Lamivudine in a Patient With Advanced Renal Cell Carcinoma Treated With Everolimus. American Journal of Therapeutics 2016; 23(1): e300 doi: 10.1097/MJT.0000000000000005
|
| 10 |
Claudia Bozza, Marika Cinausero, Donatella Iacono, Fabio Puglisi. Hepatitis B and cancer: A practical guide for the oncologist. Critical Reviews in Oncology/Hematology 2016; 98: 137 doi: 10.1016/j.critrevonc.2015.10.017
|
| 11 |
Leonardo Calle García, Pilar Tajada Alegre, Victoria M. Villalta Robles, Ana Avellón Calvo, M. Astrid Rodríguez Gómez, Manuel Heras Benito, Rebeca Amo Alonso, Carmen Martín Varas, Giomar Urzola Rodríguez, M. José Fernández-Reyes Luis. Reactivation of hepatitis B virus in patient that rests dialysis after renal transplantation. How can we prevent it or anticipate it in diagnosis?. Nefrología (English Edition) 2020; 40(4): 477 doi: 10.1016/j.nefroe.2019.06.008
|
| 12 |
Eleonora Teplinsky, Derrick Cheung, Ilan Weisberg, Ramon E. A. Jacobs, Martin Wolff, James Park, Kent Friedman, Franco Muggia, Komal Jhaveri. Fatal hepatitis B reactivation due to everolimus in metastatic breast cancer: case report and review of literature. Breast Cancer Research and Treatment 2013; 141(2): 167 doi: 10.1007/s10549-013-2681-0
|
| 13 |
Mauro Viganò, Giuseppe Serra, Giovanni Casella, Glenda Grossi, Pietro Lampertico. Reactivation of hepatitis B virus during targeted therapies for cancer and immune-mediated disorders. Expert Opinion on Biological Therapy 2016; 16(7): 917 doi: 10.1080/14712598.2016.1177017
|
| 14 |
Mauro Viganò, Marta La Milia, Maria Vittoria Grassini, Nicola Pugliese, Massimo De Giorgio, Stefano Fagiuoli. Hepatotoxicity of Small Molecule Protein Kinase Inhibitors for Cancer. Cancers 2023; 15(6): 1766 doi: 10.3390/cancers15061766
|
| 15 |
Kirsty Wai-Chung Lee, Stephen Lam Chan. Hepatotoxicity of targeted therapy for cancer. Expert Opinion on Drug Metabolism & Toxicology 2016; 12(7): 789 doi: 10.1080/17425255.2016.1190831
|
| 16 |
Charat Thongprayoon, Wisit Kaewput, Konika Sharma, Karn Wijarnpreecha, Napat Leeaphorn, Patompong Ungprasert, Ankit Sakhuja, Franco H Cabeza Rivera, Wisit Cheungpasitporn. Outcomes of kidney transplantation in patients with hepatitis B virus infection: A systematic review and meta-analysis. World Journal of Hepatology 2018; 10(2): 337-346 doi: 10.4254/wjh.v10.i2.337
|
| 17 |
Yu Shi, Min Zheng. Hepatitis B virus persistence and reactivation. BMJ 2020; : m2200 doi: 10.1136/bmj.m2200
|
| 18 |
Isabel Ruiz-Camps, Juan Aguilar-Company. Risk of infection associated with targeted therapies for solid organ and hematological malignancies. Therapeutic Advances in Infectious Disease 2021; 8: 204993612198954 doi: 10.1177/2049936121989548
|
| 19 |
Leonardo Calle García, Pilar Tajada Alegre, Victoria M. Villalta Robles, Ana Avellón Calvo, M. Astrid Rodríguez Gómez, Manuel Heras Benito, Rebeca Amo Alonso, Carmen Martín Varas, Giomar Urzola Rodríguez, M. José Fernández-Reyes Luis. Reactivación silenciosa del virus de la hepatitis B en paciente que reinicia diálisis tras trasplante renal. ¿Cómo podemos prevenirlo o anticiparlo en el diagnóstico?. Nefrología 2020; 40(4): 477 doi: 10.1016/j.nefro.2019.06.006
|
| 20 |
Mark D. Muthiah, En Ying Tan, Sin Hui Melissa Chua, Daniel Q. Y. Huang, Glenn K. Bonney, Alfred W. C. Kow, Seng Gee Lim, Yock Young Dan, Poh Seng Tan, Guan Huei Lee, Boon Leng Lim. Nucleoside analog monotherapy for prophylaxis in Hepatitis B liver transplant patients is safe and efficacious. Hepatology International 2020; 14(1): 57 doi: 10.1007/s12072-019-10011-2
|
| 21 |
Smaragdi Marinaki, Kyriaki Kolovou, Stratigoula Sakellariou, John N Boletis, Ioanna K Delladetsima. Hepatitis B in renal transplant patients. World Journal of Hepatology 2017; 9(25): 1054-1063 doi: 10.4254/wjh.v9.i25.1054
|
| 22 |
Ivan Noreña, Mario Fernández-Ruiz, José María Aguado. Viral infections in the biologic therapy era. Expert Review of Anti-infective Therapy 2018; 16(10): 781 doi: 10.1080/14787210.2018.1521270
|
| 23 |
Isabel Ruiz-Camps, Juan Aguilar-Company. Epidermal Growth Factor Receptor Inhibitors and Other Tyrosine Kinase Inhibitors for Solid Tumors. Infectious Disease Clinics of North America 2020; 34(2): 257 doi: 10.1016/j.idc.2020.02.005
|
| 24 |
Zhuo Wang, Wei Jin, Hongchuan Jin, Xian Wang. mTOR in Viral Hepatitis and Hepatocellular Carcinoma: Function and Treatment. BioMed Research International 2014; 2014: 1 doi: 10.1155/2014/735672
|
| 25 |
Cheng-Shyong Chang, Chien-Yu Tsai, Sheng-Lei Yan. Hepatitis B reactivation in patients receiving targeted therapies. Hematology 2017; 22(10): 592 doi: 10.1080/10245332.2017.1321882
|
| 26 |
M. Reinwald, J.T. Silva, N.J. Mueller, J. Fortún, C. Garzoni, J.W. de Fijter, M. Fernández-Ruiz, P. Grossi, J.M. Aguado. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors). Clinical Microbiology and Infection 2018; 24: S53 doi: 10.1016/j.cmi.2018.02.009
|
| 27 |
C.S. Voican, O. Mir, P. Loulergue, M. Dhooge, C. Brezault, J. Dréanic, S. Chaussade, S. Pol, R. Coriat. Hepatitis B virus reactivation in patients with solid tumors receiving systemic anticancer treatment. Annals of Oncology 2016; 27(12): 2172 doi: 10.1093/annonc/mdw414
|
| 28 |
Carine Mauro, Victor Hugo Fonseca de Jesus, Milton Barros, Frederico Perego Costa, Rui F. Weschenfelder, Nathalia D'Agustini, Martin Angel, Romina Luca, Jose Eduardo Nuñez, Juan Manuel O'Connor, Rachel P. Riechelmann. Opportunistic and Serious Infections in Patients with Neuroendocrine Tumors Treated with Everolimus: A Multicenter Study of Real-World Patients. Neuroendocrinology 2021; 111(7): 631 doi: 10.1159/000508632
|
| 29 |
Xinying Zhou, Yijin Wang, Herold J. Metselaar, Harry L.A. Janssen, Maikel P. Peppelenbosch, Qiuwei Pan. Rapamycin and everolimus facilitate hepatitis E virus replication: Revealing a basal defense mechanism of PI3K-PKB-mTOR pathway. Journal of Hepatology 2014; 61(4): 746 doi: 10.1016/j.jhep.2014.05.026
|
| 30 |
Z. Liu, L. Jiang, G. Liang, E. Song, W. Jiang, Y. Zheng, C. Gong. Hepatitis B virus reactivation in breast cancer patients undergoing chemotherapy: A review and meta‐analysis of prophylaxis management. Journal of Viral Hepatitis 2017; 24(7): 561 doi: 10.1111/jvh.12672
|